Future research efforts in the field are warranted to better elucidate the real impact of targeted agents including pertuzumab (recently approved for women with HER2-positive early breast cancer) on women’s ovarian reserve (e.g. by evaluating the dynamic of anti-mullerian hormone levels before and after treatment [8]). Here, ERBB2 is linked to breast carcinoma.